BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 21529957)

  • 1. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.
    Sultan MB; Zhou D; Loftus J; Dombi T; Ice KS;
    Ophthalmology; 2011 Jun; 118(6):1107-18. PubMed ID: 21529957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham.
    Loftus JV; Sultan MB; Pleil AM;
    Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7498-505. PubMed ID: 21896838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.
    Cunningham ET; Adamis AP; Altaweel M; Aiello LP; Bressler NM; D'Amico DJ; Goldbaum M; Guyer DR; Katz B; Patel M; Schwartz SD;
    Ophthalmology; 2005 Oct; 112(10):1747-57. PubMed ID: 16154196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.
    Wroblewski JJ; Wells JA; Adamis AP; Buggage RR; Cunningham ET; Goldbaum M; Guyer DR; Katz B; Altaweel MM;
    Arch Ophthalmol; 2009 Apr; 127(4):374-80. PubMed ID: 19365011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.
    Adamis AP; Altaweel M; Bressler NM; Cunningham ET; Davis MD; Goldbaum M; Gonzales C; Guyer DR; Barrett K; Patel M;
    Ophthalmology; 2006 Jan; 113(1):23-8. PubMed ID: 16343627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema].
    Ishibashi T; Yuzawa M; Yoshimura N; Ohji M; Ishida S; Isogawa N; Esaka E
    Nippon Ganka Gakkai Zasshi; 2014 Sep; 118(9):773-82. PubMed ID: 25318186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
    Heier JS; Korobelnik JF; Brown DM; Schmidt-Erfurth U; Do DV; Midena E; Boyer DS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Vitti R; Berliner AJ; Zeitz O; Metzig C; Holz FG
    Ophthalmology; 2016 Nov; 123(11):2376-2385. PubMed ID: 27651226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
    Brown DM; Nguyen QD; Marcus DM; Boyer DS; Patel S; Feiner L; Schlottmann PG; Rundle AC; Zhang J; Rubio RG; Adamis AP; Ehrlich JS; Hopkins JJ;
    Ophthalmology; 2013 Oct; 120(10):2013-22. PubMed ID: 23706949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema.
    Callanan DG; Gupta S; Boyer DS; Ciulla TA; Singer MA; Kuppermann BD; Liu CC; Li XY; Hollander DA; Schiffman RM; Whitcup SM;
    Ophthalmology; 2013 Sep; 120(9):1843-51. PubMed ID: 23706947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
    Nguyen QD; Brown DM; Marcus DM; Boyer DS; Patel S; Feiner L; Gibson A; Sy J; Rundle AC; Hopkins JJ; Rubio RG; Ehrlich JS;
    Ophthalmology; 2012 Apr; 119(4):789-801. PubMed ID: 22330964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.
    Do DV; Schmidt-Erfurth U; Gonzalez VH; Gordon CM; Tolentino M; Berliner AJ; Vitti R; Rückert R; Sandbrink R; Stein D; Yang K; Beckmann K; Heier JS
    Ophthalmology; 2011 Sep; 118(9):1819-26. PubMed ID: 21546089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal aflibercept for diabetic macular edema.
    Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
    Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
    Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
    Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
    Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
    Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study.
    Gillies MC; Lim LL; Campain A; Quin GJ; Salem W; Li J; Goodwin S; Aroney C; McAllister IL; Fraser-Bell S
    Ophthalmology; 2014 Dec; 121(12):2473-81. PubMed ID: 25155371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study.
    Augustin AJ; Kuppermann BD; Lanzetta P; Loewenstein A; Li XY; Cui H; Hashad Y; Whitcup SM;
    BMC Ophthalmol; 2015 Oct; 15():150. PubMed ID: 26519345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
    ; Chakravarthy U; Adamis AP; Cunningham ET; Goldbaum M; Guyer DR; Katz B; Patel M
    Ophthalmology; 2006 Sep; 113(9):1508.e1-25. PubMed ID: 16828500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study.
    Li X; Dai H; Li X; Han M; Li J; Suhner A; Lin R; Wolf S;
    Graefes Arch Clin Exp Ophthalmol; 2019 Mar; 257(3):529-541. PubMed ID: 30645696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
    Ruiz-Moreno JM
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.
    Heier JS; Clark WL; Boyer DS; Brown DM; Vitti R; Berliner AJ; Kazmi H; Ma Y; Stemper B; Zeitz O; Sandbrink R; Haller JA
    Ophthalmology; 2014 Jul; 121(7):1414-1420.e1. PubMed ID: 24679444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.